{"id":"W3124365819","doi":"10.1111/pcmr.12960","title":"First‐line atezolizumab monotherapy in patients with advanced <i>BRAF</i><sup>V600</sup> wild‐type melanoma","year":2021,"lang":"en","type":"article","venue":"Pigment Cell & Melanoma Research","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":29,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Internal medicine; Pembrolizumab; Adverse effect; Melanoma; Oncology; Gastroenterology; Cohort; Response Evaluation Criteria in Solid Tumors; Surgery; Progressive disease; Cancer; Disease; Cancer research; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001419354,0.0006050442,0.0009922015,0.0008817943,0.0003531074,0.0001702662,0.000636797,0.0003297472,0.008860478],"category_scores_gemma":[0.0001988141,0.0005188507,0.000203,0.002666647,0.0003525946,0.0002757349,0.0003476774,0.001762454,0.0006142508],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001207455,"about_ca_system_score_gemma":0.001019339,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003431827,"about_ca_topic_score_gemma":0.0002341335,"domain_scores_codex":[0.9914768,0.0007200066,0.0008338729,0.001490078,0.003388774,0.002090468],"domain_scores_gemma":[0.9953069,0.0006057237,0.0001232149,0.001794329,0.001422806,0.0007470411],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.04115862,0.0116653,0.7726339,0.001105465,0.0007343651,0.00362944,0.004060474,0.002326262,0.06259111,0.0001584194,0.00417364,0.09576305],"study_design_scores_gemma":[0.1058157,0.02736679,0.3342488,0.001470362,0.0001471377,0.0001397397,0.001892096,0.002847976,0.2204357,0.0005054965,0.3028883,0.002241938],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9772755,0.002358673,0.00002923299,0.001894566,0.0001275583,0.002728857,0.00003161762,0.0001032788,0.01545071],"genre_scores_gemma":[0.9705516,0.002858137,0.0009523889,0.0003132707,0.0003030587,0.0003332306,0.0004037103,0.0002385962,0.02404598],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4383851,"threshold_uncertainty_score":0.9997263,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03026515582306657,"score_gpt":0.3172720341146936,"score_spread":0.287006878291627,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}